US Starts Clinical Trial For Universal Flu Vaccine
Date
9/15/2023 10:00:06 PM
(MENAFN- IANS) Los Angeles, Sep 16 (IANS) Thehas started the phase 1 clinical trial of a new investigational universal flu vaccine candidate, theNational Institutes of health (NIH) announced. The trial, sponsored by theNational Institute of Allergy and InfectiDiseases (NIAID), will evaluate the investigational vaccine, named FluMos-v2, for safety and its ability to elicit an immune response, Xinhua news agency reported.
The vaccine candidate was designed by researchers at NIAID's Vaccine Research Centre. It is designed to induce antibodies against many different influenza vistrains by displaying part of the influenza vihemagglutinin protein in repeating patterns on self-assembling nanoparticle scaffolds. Exposure to these harmless fragments of viproteins prepares the immune system to recognise and fight the actual virus.
When tested in animals, the experimental vaccine resulted in robust antibody responses, according to the NIH on Friday.
The new clinical trial is expected to enroll 24 healthy volunteers, aged between 18 to 50 years, who will receive two intramuscular injections of the FluMos-v2 vaccine candidate. These injections will be given 16 weeks apart.
For 40 weeks after their first vaccination, participants will receive regular follow-up phone calls and examinations to track their responses to the experimental vaccine.
Most seasonal flu vaccines are designed to train the immune system to defend against three or four different common strains of flu, but a "universal" influenza vaccine might someday provide protection against many more, according to the NIH.
--IANS
int/khz
MENAFN15092023000231011071ID1107079771
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.